Bg pattern

TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Teicoplanin Hikma 200 mg powder for solution for injection and infusion EFG

Teicoplanin Hikma 400 mg powder for solution for injection and infusion EFG

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • If you experience any side effects, talk to your doctor, pharmacist or nurse, even if you think they might be unrelated to this medicine. See section 4.

Contents of the package leaflet

  1. What is Teicoplanin Hikma and what is it used for
  2. What you need to know before you use Teicoplanin Hikma
  3. How to use Teicoplanin Hikma
  4. Possible side effects
  5. Storage of Teicoplanin Hikma
  6. Contents of the pack and further information

1. What is Teicoplanin Hikma and what is it used for

Teicoplanin Hikma is an antibiotic. It contains a medicine called “teicoplanin”. It works by killing the bacteria that cause infections in your body.

Antibiotics are used to treat bacterial infections and will not work for viral infections such as flu or the common cold.

It is important that you follow the instructions regarding dose, administration interval, and treatment duration as indicated by your doctor.

Do not store or reuse this medicine. If you have any leftover antibiotic after finishing treatment, return it to the pharmacy for proper disposal. Do not throw medicines down the drain or in the trash.

Teicoplanin Hikma is used in adults and children (including newborns) to treat infections in:

  • the skin and under the skin - sometimes called “soft tissues”
  • bones and joints
  • the lung
  • the urinary tract
  • the heart – sometimes called “endocarditis”
  • the abdominal wall - peritonitis
  • the blood, when caused by one of the conditions listed above

Teicoplanin can be used to treat some infections caused by the bacteria Clostridioides difficilein the intestine. In this case, the solution should be taken by mouth.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Teicoplanin Hikma

Do not use Teicoplanin Hikma:

  • if you are allergic to teicoplanin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before starting Teicoplanin Hikma if:

  • you are allergic to an antibiotic called “vancomycin”
  • you have had a reddening of the upper body (red man syndrome)
  • you have a low platelet count (thrombocytopenia)
  • you have kidney problems
  • you are taking other medicines that may cause hearing and/or kidney problems.

You may have regular tests to check if your blood, kidneys, and/or liver are working properly (see “Other medicines and Teicoplanin Hikma”).

If any of the above applies to you (or if you are not sure), tell your doctor, pharmacist or nurse before using Teicoplanin Hikma.

Severe skin reactions have been reported with the use of teicoplanin, including Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). If you develop a severe rash or other skin symptoms as described in section 4, stop taking Teicoplanin Hikma and contact your doctor or seek medical attention immediately.

Tests

During treatment, you may have tests to check your blood, kidneys, liver, and/or hearing. This is more likely if:

  • your treatment is going to last a long time
  • you need to be treated with high loading doses (12 mg/kg twice a day)
  • you have kidney problems
  • you are taking or may take other medicines that may affect your nervous system, kidneys, and hearing.

In people who are being treated with Teicoplanin Hikma for a long time, bacteria that are not affected by the antibiotic may grow more than usual – your doctor will check for this.

Other medicines and Teicoplanin Hikma

Tell your doctor, pharmacist or nurse if you are using, have recently used or might use any other medicines. This is because Teicoplanin Hikma may affect how other medicines work. Also, some medicines may affect how Teicoplanin Hikma works.

In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:

  • Aminoglycosides, as they should not be mixed with Teicoplanin Hikma in the same injection. They may also cause hearing and/or kidney problems.
  • amphotericin B – a medicine that treats fungal infections that may cause hearing and/or kidney problems
  • cyclosporin – a medicine that affects the immune system that may cause hearing and/or kidney problems
  • cisplatin – a medicine that treats malignant tumors that may cause hearing and/or kidney problems
  • water pills (such as furosemide) also called “diuretics” that may cause hearing and/or kidney problems.

If any of the above applies to you (or if you are not sure), tell your doctor, pharmacist or nurse before using Teicoplanin Hikma.

Pregnancy, breast-feeding and fertility

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before using this medicine. They will decide whether you should be given this medicine while pregnant. There may be a potential risk of problems in the inner ear and kidneys.

Tell your doctor if you are breast-feeding before they give you this medicine. They will decide whether you can continue breast-feeding while being given Teicoplanin Hikma.

Animal reproduction studies have not shown any evidence of fertility problems.

Driving and using machines

You may have headaches or feel dizzy while being treated with Teicoplanin Hikma. If this happens, do not drive or use tools or machines.

Teicoplanin Hikma contains sodium

This medicine contains less than 23 mg of sodium (1mmol) per vial; this is essentially “sodium-free”.

3. How to use Teicoplanin Hikma

The recommended dose is:

Adults and children (12 years or older) without kidney problems

Infections of the skin and soft tissues, lung, and urinary tract

  • Initial dose (for the first three doses): 400 mg (this is equivalent to 6 mg per kilogram of body weight), given every 12 hours, by injection into a vein or muscle
  • Maintenance dose: 400 mg (this is equivalent to 6 mg per kilogram of body weight), given once a day, by injection into a vein or muscle

Infections of the bones and joints, and heart

  • Initial dose (for the first three to five doses): 800 mg (this is equivalent to 12 mg per kilogram of body weight), given every 12 hours, by injection into a vein or muscle
  • Maintenance dose: 800 mg (this is equivalent to 12 mg per kilogram of body weight), given once a day, by injection into a vein or muscle

Infection caused by the bacteria Clostridioides difficile

The recommended dose is 100 to 200 mg by mouth, twice a day for 7 to 14 days.

Adults and elderly patients with kidney problems

If you have kidney problems, it will normally be necessary to reduce your dose after the fourth day of treatment:

  • For people with mild to moderate kidney problems - the maintenance dose will be given every two days, or half of the maintenance dose will be given once a day.
  • For people with severe kidney problems and on hemodialysis - the maintenance dose will be given every three days, or one-third of the maintenance dose will be given once a day.

Treatment of peritonitis in patients on peritoneal dialysis

The initial dose is 6 mg per kilogram of body weight, as a single injection into a vein, followed by:

  • Week one: 20 mg/l in each dialysis bag
  • Week two: 20 mg/l in alternate dialysis bags
  • Week three: 20 mg/l in the dialysis bags used at night.

Babies (from birth to 2 months of age)

  • Initial dose (on day one): 16 mg per kilogram of body weight, as an infusion into a vein through a drip.
  • Maintenance dose: 8 mg per kilogram of body weight, given once a day, as an infusion into a vein through a drip.

Children (from 2 months to 12 years of age)

  • Initial dose (for the first three doses): 10 mg per kilogram of body weight, given every 12 hours, by injection into a vein.
  • Maintenance dose: 6 to 10 mg per kilogram of body weight, given once a day, by injection into a vein.

How Teicoplanin Hikma is given

This medicine will normally be given to you by a doctor or nurse.

  • It will be given by injection into a vein (intravenously) or into a muscle (intramuscularly).
  • It can also be given by infusion into a vein through a drip.

In babies from birth to two months, it will only be given by infusion.

For the treatment of certain infections, the solution may be given by mouth (orally).

If you are given too much Teicoplanin Hikma

It is unlikely that your doctor or nurse will give you too much medicine. However, if you think you have been given too much Teicoplanin Hikma or if you are concerned, talk to your doctor or nurse immediately.

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 5620420, indicating the medicine and the amount taken.

If you miss a dose of Teicoplanin Hikma

Your doctor or nurse will have instructions on when to give you Teicoplanin Hikma. It is unlikely that they will not give you the medicine as prescribed. However, if you are concerned, talk to your doctor or nurse.

If you stop treatment with Teicoplanin Hikma

Do not stop this treatment without talking to your doctor, pharmacist or nurse first.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Stop treatment immediately and contact a doctor or nurse if you notice any of the following serious side effects – you may need urgent medical treatment:

Uncommon(may affect up to 1 in 100 people)

  • sudden life-threatening allergic reaction – the signs may include: difficulty breathing or wheezing, swelling, rash, itching, fever, chills

Rare(may affect up to 1 in 1,000 people)

  • reddening of the upper body

Frequency not known(cannot be estimated from the available data)

  • appearance of blisters on the skin, mouth, eyes, or genitals – these could be signs of a condition called “toxic epidermal necrolysis” or “Stevens-Johnson syndrome”
  • red, scaly rash all over your body with bumps under the skin (including skin folds, chest, abdomen, back, and arms) and blisters, accompanied by fever - these may be symptoms of something called "acute generalized exanthematous pustulosis (AGEP)".
  • "drug reaction with eosinophilia and systemic symptoms (DRESS)". DRESS appears initially as flu-like symptoms and a rash on the face, then a prolonged rash with a high temperature, increased liver enzymes seen in blood tests, and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.

Tell your doctor or nurse immediately if you experience any of the above side effects.

Tell your doctor or nurse immediately if you experience any of the following serious side effects – you may need urgent medical treatment:

Uncommon(may affect up to 1 in 100 people)

  • inflammation and clot in a vein
  • difficulty breathing and wheezing (bronchospasm)
  • if you get more infections than usual – these could be signs of a decrease in your blood cell count

Frequency not known(cannot be estimated from the available data)

  • lack of white blood cells in the blood – the signs may include: fever, severe chills, sore throat or mouth ulcers (agranulocytosis)
  • kidney problems or changes in kidney function – shown in tests. The frequency or severity of kidney problems may increase if you receive higher doses.
  • seizures
  • low levels of all types of blood cells

Tell your doctor or nurse immediately if you experience any of the above side effects.

Other side effects

Talk to your doctor, pharmacist or nurse if you get any of the following side effects:

Common(may affect up to 1 in 10 people)

  • skin rash, redness, itching
  • pain
  • fever

Uncommon(may affect up to 1 in 100 people)

  • decrease in platelet count
  • increase in blood levels of liver enzymes
  • increase in blood levels of creatinine (to check your kidney)
  • hearing loss, ringing in the ears or the feeling that you or your surroundings are spinning
  • nausea or vomiting, diarrhea
  • dizziness or headache

Rare(may affect up to 1 in 1,000 people)

  • infection (abscesses)

Frequency not known(cannot be estimated from the available data)

  • problems at the injection site – such as skin redness, pain, or swelling

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist or nurse, even if you think they might be unrelated to this medicine. You can also report side effects directly to the Spanish Medicines Agency's Pharmacovigilance System for Human Use: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Teicoplanin Hikma

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions.

Information about the storage and use of Teicoplanin Hikma once it has been reconstituted and is ready to use is detailed in “Practical information for healthcare professionals on the preparation and handling of Teicoplanin Hikma”.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

Composition of Teicoplanin Hikma

  • The active ingredient is teicoplanin. Each vial contains 200 mg or 400 mg of teicoplanin.
  • The other components are sodium chloride and sodium hydroxide.

Appearance of the Product and Container Content

Teicoplanin Hikma is a white to yellowish lyophilized powder. The powder is packaged in 10 ml vials for Teicoplanin Hikma 200 mg and 20 ml vials for Teicoplanin Hikma 400 mg.

Teicoplanin Hikma is marketed in packs of 1 vial or 10 vials.

Only some package sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Hikma Farmacêutica (Portugal), S.A.

Estrada do Rio da Mó 8, 8A e 8B – Fervença

2705-906 Terrugem SNT, Portugal

Tel.: +351 219608410

e-mail: [email protected]

Manufacturer:

Hikma Italia S.P.A.

Viale Certosa, 10

27100 Pavia

Italy

Tel.: +39 0382 1751801

Fax: +39 0382 422745

e-mail: [email protected]

For further information about this medicinal product, please contact the local representative of the marketing authorization holder:

Hikma España, S.L.U.

Calle Anabel Segura nº11, Edificio A, planta 1ª, oficina 2

28108 - Alcobendas, Madrid

Spain

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

AustriaTeicoplanin Hikma 200 mg Powder for solution for injection/infusion or oral solution

Teicoplanin Hikma 400 mg Powder for solution for injection/infusion or oral solution

SpainTeicoplanina Hikma 200 mg powder for injectable solution and perfusion EFG

Teicoplanina Hikma 400 mg powder for injectable solution and perfusion EFG

FranceTeicoplanine Hikma 200 mg powder for injectable solution/perfusion or oral solution

Teicoplanine Hikma 400 mg powder for injectable solution/perfusion or oral solution

IrelandTeicoplanin Hikma 200mg powder for solution for injection/infusion or oral solution

Teicoplanin Hikma 400mg powder for solution for injection/infusion or oral solution

ItalyTeicoplanina Hikma 200mg powder for injectable solution/infusion or oral solution

Teicoplanina Hikma 400mg powder for injectable solution/infusion or oral solution

NetherlandsTeicoplanine Hikma 200 mg powder for solution for injection/infusion or oral solution

Teicoplanine Hikma 400 mg powder for solution for injection/infusion or oral solution

PortugalTeicoplanina Hikma 200 mg Powder for injectable solution or perfusion or oral solution

Teicoplanina Hikma 400 mg Powder for injectable solution or perfusion or oral solution

United KingdomTeicoplanin Hikma 200mg powder for solution for injection/infusion or oral solution

Teicoplanin Hikma 400mg powder for solution for injection/infusion or oral solution

Date of last revision of this leaflet: November 2022

This information is intended only for healthcare professionals:

Practical information for healthcare professionals on the preparation and handling of Teicoplanin Hikma.

This medicinal product is for single use only.

Form of administration

The reconstituted solution can be injected directly or alternatively in a diluted form.

Intravenous injection will be administered either as a bolus over 3-5 minutes or as an infusion over 30 minutes.

In infants from birth to two months, it will only be administered by infusion.

The reconstituted solution can also be administered orally.

Preparation of the reconstituted solution:

  • Slowly inject 3.14 ml of water for injectable preparations into the powder vial.
  • The vial should be gently rolled between the hands until the powder is completely dissolved. If the solution becomes foamy, it should be left to stand for approximately 15 minutes.

The reconstituted solutions will contain 200 mg of teicoplanin in 3.0 ml and 400 mg of teicoplanin in 3.0 ml.

Only clear and yellowish solutions should be used.

The final solution is isotonic with plasma and has a pH of 6.0-8.0.

Nominal content of teicoplanin per vial

200 mg

400 mg

Vial volume with powder

10 ml

20 ml

Volume containing the nominal dose of teicoplanin (extracted using a 5 ml syringe and 23 G needle)

3.0 ml

3.0 ml

Preparation of the diluted solution before infusion

Teicoplanin Hikma can be administered in the following infusion solutions:

  • Sodium chloride 9 mg/ml (0.9%) solution
  • Ringer's solution
  • Ringer-lactate solution
  • 5% glucose injection
  • 10% glucose injection
  • Solution with 0.18% sodium chloride and 4% glucose
  • Solution with 0.45% sodium chloride and 5% glucose
  • Peritoneal dialysis solution containing 1.36% or 3.86% glucose solution.

Shelf life of the reconstituted solution:

Chemical and physical stability in use of the reconstituted solution with water for injectable preparations has been demonstrated for 24 hours between 2°C and 8°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not exceed 24 hours between 2°C and 8°C, unless the reconstitution has been carried out in controlled and validated aseptic conditions.

Shelf life of the diluted medicinal product

The chemical and physical stability in use of the reconstituted solution prepared as recommended has been demonstrated for 24 hours between 2°C and 8°C.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, the in-use storage times and conditions are the responsibility of the user and normally should not exceed 24 hours between 2°C and 8°C, unless the reconstitution/dilution has been carried out in controlled and validated aseptic conditions.

Disposal

Disposal of the unused medicinal product and all materials that have come into contact with it should be carried out in accordance with local regulations.

Online doctors for TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION

Discuss questions about TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (764)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50

Frequently Asked Questions

Is a prescription required for TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION?
TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION?
The active ingredient in TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION is teicoplanin. This information helps identify medicines with the same composition but different brand names.
Who manufactures TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION?
TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION is manufactured by Hikma Farmaceutica (Portugal) S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to TEICOPLANIN HIKMA 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION?
Other medicines with the same active substance (teicoplanin) include TARGOCID 400 mg POWDER AND SOLVENT FOR INJECTION AND INFUSION SOLUTION, TEICOPLANIN ACCORD 200 mg POWDER FOR INJECTABLE SOLUTION AND FOR INFUSION, TEICOPLANIN ACCORD 400 mg POWDER FOR INJECTION AND INFUSION SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media